Uprising is an early-stage venture firm. Its connection to the psychedelic field is participation in the US$12 million 2021 Series A of Journey Colab, a developer of a pipeline of psychedelic compounds (beginning with mescaline) built around a stakeholder-trust model.
Investor Context
Venture CapitalInvestment Context
This stakeholder is listed as a Venture Capital Fund within Venture Capital. Its public geography context is global. Public stage focus is not listed yet. Psychedelic-market posture: Psychedelic-Adjacent Focus.
Public Portfolio Examples
- Journey ColabSeries A - $12 million - Sep 7, 2021
Created from documented participation in 1 psychedelic financing round. Profile details beyond documented deals are unverified.
Investor Type
Venture Capital Fund
Geographic Scope
Global
Psychedelic Focus
Psychedelic-Adjacent Focus
Engagement
Active
Investment Stage Focus
Stage focus is not listed yet.
Investment Focus Areas
Focus areas are not listed yet.
Recorded Investments
Sep 7, 2021
Series A - $12 million
Fenwick Represents Journey Colab in $12 Million Series A Financing